Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

  • Uribe-Herranz, Mireia
  • Oliver-Caldés, Aina
  • Martínez-Micaelo, Neus
  • Español-Rego, Marta
  • Val-Casals, Maria
  • Martínez-Soler, Roberto
  • Rubio-Garcia, Elisa
  • Brunello, Valeria
  • Mihelic, Erik Z.
  • Klein-González, Nela
  • Benítez-Ribas, Daniel
  • Amigó, Núria
  • Vergara, Andrea
  • Ortiz-Maldonado, Valentín
  • Rodríguez-Lobato, Luis Gerardo
  • Delgado, Julio
  • Ortiz de Landazuri, Iñaki
  • González-Calle, Verónica
  • Cabañas, Valentín
  • Martín-Antonio, Beatriz
  • Pérez-Amill, Lorena
  • Reguera-Ortega, Juan Luis
  • Rodríguez-Otero, Paula
  • Paiva, Bruno
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • Pascal, Mariona
  • Urbano-Ispizúa, Álvaro
  • González-Navarro, Europa Azucena
  • Fernández de Larrea, Carlos
  • Juan, Manel
Multiple myeloma remains incurable despite advances in immunotherapies like chimeric antigen receptor (CAR) T-cell therapy. This study investigates the role of metabolites and gut microbiota in clinical outcomes in patients treated with the humanized B-cell maturation antigen (BCMA)-directed CAR-T therapy ARI0002h. Stool metabolites, particularly succinate, were associated with CAR T-cell phenotypes and persistence in patients. In CAR T-cell culture, succinate supplementation enhanced CD4+ central memory phenotype and respiratory capacity. In a murine myeloma model, a succinate-enhancing diet significantly improved CAR T-cell persistence and showed a trend toward better tumor control. Furthermore, Acidaminococcaceae, Monoglobaceae, or Akkermansiaceae, along with specific metabolites, were associated with CAR T-cell clinical outcomes. These multimodal profiles were integrated into response models, including one that identified patients likely to achieve a complete response by days 100 and 180 after infusion. These findings suggest that metabolites and gut microbiota correlate with CAR T-cell therapy responses and can be a valuable tool for risk assessment., This work has been partially supported by grants from the Instituto de Salud Carlos III (cofunded by the European Union), Spanish Ministry of Health (FIS PI18/00775, PICI18/00012 ICI19/00025, PI19/00669, PI22/00647, and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional “una manera de hacer Europa” 2021SGR01292 (AGAUR; Generalitat de Catalunya), “La Caixa” Foundation (CP042702/LCF/PR/GN18/50310007), RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019), Red de Terapia Celular (RD16/0011/0005), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), Asociación Española Contra el Cáncer (LABAE21971FERN), and Fundació Bosch I Aymerich., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells

  • Battram, Anthony M|||0000-0002-9179-0639
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Suárez Lledó, Maria
  • Lozano, Miquel|||0000-0003-2593-833X
  • Bosch, Miquel|||0000-0002-7103-2574
  • Martínez Cibrián, Núria|||0000-0002-8688-1202
  • Cid, Joan|||0000-0001-5445-4508
  • Moreno, David F.
  • Rodríguez Lobato, Luis Gerardo|||0000-0001-5694-0921
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
Autologous cell immunotherapy using B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells is an effective novel treatment for multiple myeloma (MM). This therapy has only been used for relapsed and refractory patients, at which stage the endogenous T cells used to produce the CAR-T cells are affected by the immunosuppressive nature of advanced MM and/or side effects of previous therapies. An alternative pool of "fitter" T cells is found in leukocytoapheresis products that are routinely collected to obtain hematopoietic progenitor cells for autologous stem cell transplantation (ASCT) early in the treatment of MM. However, to mobilize the progenitor cells, patients are dosed with granulocyte colony-stimulating factor (G-CSF), which is reported to adversely affect T cell proliferation, function, and differentiation. Here, we aimed to first establish whether G-CSF treatment negatively influences T cell phenotype and to ascertain whether previous exposure of T cells to G-CSF is deleterious for anti-BCMA CAR-T cells. We observed that G-CSF had a minimal impact on T cell phenotype when added in vitro or administered to patients. Moreover, we found that CAR-T cell fitness and anti-tumor activity were unaffected when generated from G-CSF-exposed T cells. Overall, we showed that ASCT apheresis products are a suitable source of T cells for anti-BCMA CAR-T cell manufacture.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease

  • Isola, Ignacio
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Moreno, David F.
  • Mena, Mari Pau
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Paré Brunet, Laia
  • Rodríguez Lobato, Luis Gerardo|||0000-0001-5694-0921
  • Martín-Antonio, B|||0000-0003-0612-2693
  • Cibeira, María Teresa|||0000-0002-4036-754X
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Prat, Aleix|||0000-0003-2377-540X
  • Lozano, Ester|||0000-0002-6307-9807
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
Background: We previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with higher risk of progressing who could benefit from early treatment. In this work, we analyzed differences in the immune bone marrow (BM) microenvironment in SMM to better understand the role of immune surveillance in disease progression and to identify immune biomarkers associated to higher risk of progression. Methods: Gene expression analysis of BM cells from 28 patients with SMM, 22 patients with monoclonal gammopathy of undetermined significance (MGUS) and 22 patients with symptomatic MM was performed by using Nanostring Technology. Results: BM cells in SMM compared to both MGUS and symptomatic MM showed upregulation of genes encoding for key molecules in cytotoxicity. However, some of these cytotoxic molecules positively correlated with inhibitory immune checkpoints, which may impair the effector function of BM cytotoxic cells. Analysis of 28 patients with SMM revealed 4 distinct clusters based on immune composition and activation markers. Patients in cluster 2 showed a significant increase in expression of cytotoxic molecules but also inhibitory immune checkpoints compared to cluster 3, suggesting the presence of cytotoxic cells with an exhausted phenotype. Accordingly, patients in cluster 3 had a significantly longer progression free survival. Finally, individual gene expression analysis showed that higher expression of TNF superfamily members (TNF, TNFAIP3, TNFRSF14) was associated with shorter progression free survival. Conclusions: Our results suggest that exhausted cytotoxic cells are associated to high-risk patients with SMM. Biomarkers overexpressed in patients with this immune gene profile in combination with clinical parameters and PC characterization may be useful to identify SMM patients with higher risk of progression.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Il-15 enhances the persistence and function of bcma-targeting car-t cells compared to il-2 or il-15/il-7 by limiting car-t cell dysfunction and differentiation

  • Battram, Anthony M.|||0000-0002-9179-0639
  • Bachiller, Mireia|||0000-0002-6153-4722
  • Lopez, Victor
  • Fernandez de Larrea Rodriguez, Carlos
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Martín-Antonio, B.|||0000-0003-0612-2693
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of B-lymphoid malignancies. For multiple myeloma (MM), B-cell maturation antigen (BCMA)-targeted CAR-T cells have achieved outstanding complete response rates, but unfortunately, patients often relapse within a year of receiving the therapy. Increased persistence and reduced dysfunction are crucial features that enhance the durability of CAR-T cell responses. One of the factors that influence CAR-T cell in vivo longevity and loss of function, but which has not yet been extensively studied for BCMA-directed CAR-T cells, are the cytokines used during their production. We here compared the impact of IL-2, IL-15 and a combination of IL-15/IL-7 on the phenotype and function of ARI2h, an academic BCMA-directed CAR-T cell that is currently being administered to MM patients. For this study, flow cytometry, in vitro cytotoxicity assays and analysis of cytokine release were performed. In addition, ARI2h cells expanded with IL-2, IL-15, or IL-15/IL-7 were injected into MM tumor-bearing mice to assess their in vivo efficacy. We demonstrated that each of the cytokine conditions was suitable for the expansion of ARI2h cells, with clear in vitro activity. Strikingly, however, IL-15-produced ARI2h cells had improved in vivo efficacy and persistence. When explored further, it was found that IL-15 drove a less-differentiated ARI2h phenotype, ameliorated parameters related to CAR-T cell dysfunction, and lowered the release of cytokines potentially involved in cytokine release syndrome and MM progression. Moreover, we observed that IL-15 was less potent in inducing T cell senescence and DNA damage accumulation, both of which may contribute to an unfavorable CAR-T cell phenotype. These findings show the superiority of IL-15 to IL-2 and IL-15/IL-7 in the quality of anti-BCMA CAR-T cells, particularly their efficacy and persistence, and as such, could improve the duration of responses if applied to the clinical production of CAR-T cells for patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities, Laboratory tools for an early and differential diagnosis

  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Fernández, Sara
  • Ventosa-Capell, Helena
  • Palomo, Marta|||0000-0002-3261-6577
  • Martínez Sánchez, Julia
  • Ramos, Alex|||0000-0003-1333-5144
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Delgado, Julio|||0000-0002-5157-4376
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Penack, Olaf|||0000-0003-4876-802X
  • Nicolás, J.M.
  • Téllez, Adrian
  • Escolar, Ginès
  • Carreras, Enric|||0000-0002-3134-9964
  • Fernandez Aviles, Francesc|||0000-0003-3051-3926
  • Castro Rebollo, Pedro|||0000-0002-6118-8970
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. Furthermore, differential diagnosis from sepsis, highly incident in these patients, is challenging. Suitable laboratory tools could be determinant for their appropriate management. Methods Sixty-two patients treated with CAR-T cell immunotherapy for hematological malignancies (n=46 with CD19-positive diseases, n=16 with multiple myeloma) were included. Plasma samples were obtained: before CAR-T cell infusion (baseline); after 24-48 hours; at suspicion of any toxicity onset and 24-48 hours after immunomodulatory treatment. Biomarkers of endothelial dysfunction (soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble TNF receptor 1 (sTNFRI), thrombomodulin (TM), soluble suppression of tumorigenesis-2 factor (ST2), angiopoietin-2 (Ang-2)), innate immunity activation (neutrophil extracellular traps (NETs), soluble C5b-9 (sC5b-9)) and hemostasis/fibrinolysis (von Willebrand Factor antigen (VWF:Ag), ADAMTS-13 (A13), α2-antiplasmin (α2-AP), plasminogen activator inhibitor-1 antigen (PAI-1 Ag)) were measured and compared with those in cohorts of patients with sepsis and healthy donors. Results Patients who developed CAR-T cell toxicities presented increased levels of sVCAM-1, sTNFRI and ST2 at the clinical onset versus postinfusion values. Twenty-four hours after infusion, ST2 levels were good predictors of any CAR-T cell toxicity, and combination of ST2, Ang-2 and NETs differentiated patients requiring intensive care unit admission from those with milder clinical presentations. Association of Ang-2, NETs, sC5b-9, VWF:Ag and PAI-1 Ag showed excellent discrimination between severe CAR-T cell toxicities and sepsis. Conclusions This study provides relevant contributions to the current knowledge of the CAR-T cell toxicities pathophysiology. Markers of endotheliopathy, innate immunity activation and hemostatic imbalance appear as potential laboratory tools for their prediction, severity and differential diagnosis.